Fusion of Therapeutics, Imaging, Biomarker Development Leads to Advanced Realm of Healthcare Delivery

May 11, 2021 – The fusion of new therapeutics, imaging, and biomarker development is directing us into an advanced realm of healthcare delivery. Every data point counts and is critical for successful trial completion, from Phase I through Phase III and FDA submission/approval.

Our scientific and radiologic capabilities help assure the optimal use of imaging technologies and data integrity in clinical trials.

Learn more about our oncology services at https://imagingendpoints.com/imaging-services/oncology/.